Atrix to file for 3-month Leuprogel in USA
Atrix Laboratories says it plans to file for US approval to market athree-month depot formulation of Leuprogel (leuprolide acetate), its drug for prostate cancer, after positive results from a Phase III trial of the new product. Atrix recently submitted a marketing application in the USA for a one-month formulation of Leuprogel (Marketletter April 2), which will be marketed by Sanofi-Synthelabo, if approved.
Atrix' chief executive, David Bethune, told Reuters that the market opportunity for this type of drug is estimated at around $1 billion, and the company hopes to capture 30% of that total if all goes according to plan. A four-month version should be filed next year, he noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze